Choose Your Country or Region

DUB

Isoform-selective Products

USP/UBP UCH

Signaling Pathway

DUB Products

All (34)
DUB Inhibitors (34)
New DUB Products

Catalog No.	Product Name	Information	Product Use Citations
S2913	BAY 11-7082	BAY 11-7082 (BAY 11-7821) is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 with IC50 of 0.19 μM and 0.96 μM, respectively. BAY 11-7082 induces apoptosis and S phase arrest in gastric cancer cells.	Nat Cancer, 2024, 10.1038/s43018-023-00712-x Redox Biol, 2024, 76:103323 Redox Biol, 2024, 70:103072
S7130	PR-619	PR-619 is a non-selective, reversible inhibitor of the deubiquitinylating enzymes (DUBs) with EC50 of 1-20 μM in a cell-free assay. PR-619 activates autophagy.	Nat Commun, 2024, 15(1):1642 Mol Cell, 2024, 84(16):3115-3127.e11 BMC Biol, 2024, 22(1):71
S7132	P5091	P5091 is a selective and potent inhibitor of ubiquitin-specific protease 7 (USP7) with EC50 of 4.2 μM and the closely related USP47.	J Exp Clin Cancer Res, 2024, 43(1):28 Int J Mol Sci, 2024, 25(5)2768 Nat Commun, 2023, 14(1):8481
S2243	Degrasyn (WP1130)	Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT). Degrasyn (WP1130) induces apoptosis and blocks autophagy.	Clin Cancer Res, 2023, 29(2):446-457 Clin Cancer Res, 2023, 29(2):446-457 Cancer Cell Int, 2023, 23(1):207
S7888	Spautin-1	Spautin-1 is a potent and specific autophagy inhibitor, and inhibits the deubiquitinating activity of USP10 and USP13 with IC50 of ∼0.6-0.7 μM. Spautin-1 enhances apoptosis.	Nat Commun, 2024, 15(1):9463 J Adv Res, 2024, S2090-1232(24)00025-0 Cancer Lett, 2024, 604:217258
S7133	P22077	P22077 is an inhibitor of ubiquitin-specific protease USP7 with EC50 of 8.6 μM, also inhibits the closely related USP47.	Int J Mol Sci, 2024, 25(5)2768 Hepatol Commun, 2024, 8(4)e0405 EMBO Rep, 2022, e54391
S7134	IU1	IU1 is a cell-permeable, reversible and selective proteasome inhibitor of human USP14 with IC50 of 4.7 μ M, 25-fold selective to IsoT. IU1 induces autophagy.	Redox Biol, 2024, 76:103318 Antioxidants (Basel), 2024, 13(1)114 Nat Commun, 2022, 13-1:5644
S4920	b-AP15	b-AP15 (NSC687852) is a deubiquitinases inhibitor for 19S proteasomes activity of Ub-AMC cleavage with IC50 of 2.1 μM.	J Transl Med, 2024, 22(1):193 Commun Biol, 2024, 7(1):25 Science, 2023, 380(6647):eadf2018
S7529	ML323	ML323 displays reversible, nanomolar inhibitory activity and excellent selectivity toward USP1/UAF1 with IC50 of 76 nM.	Nucleic Acids Res, 2024, gkae785 Mol Med, 2024, 30(1):121 Blood Adv, 2023, 7(13):3099-3112
S7135	LDN-57444	LDN-57444 is a reversible, competitive proteasome inhibitor for Uch-L1 with IC50 of 0.88 μM, 28-fold selectivity over isoform Uch-L3.	J Transl Med, 2024, 22(1):478 Cells, 2024, 13(9)737 Mol Cells, 2023, 46(8):476-485
S3692	NEM (N-Ethylmaleimide)	NEM (N-Ethylmaleimide) is an organic compound that is derived from maleic acid. It is an irreversible inhibitor of all cysteine peptidases, with alkylation occurring at the active site thiol group. N-Ethylmaleimide (NEM) inactivates endogenous deubiquitinating enzymes (DUBs). N-Ethylmaleimide (NEM) specifically inhibits phosphate transport in mitochondria.	BMC Biol, 2024, 22(1):71 Cell Rep Med, 2023, 10.1016/j.xcrm.2023.101286 Int J Mol Sci, 2023, 25(1)423
S8288	VLX1570	VLX1570 is a competitive inhibitor of proteasome DUB activity, with an IC50 of ~10 μM in vitro.	Commun Biol, 2024, 7(1):25 PLoS One, 2022, 17(7):e0271245 Cancer Sci, 2021, 112(8):3302-3313
S6877	EOAI3402143	EOAI3402143 is a dose-dependent inhibitor of Usp9x, Usp24 and Usp5 that increases tumor cell apoptosis, and fully blocks or regresses myeloma tumors in mice.	Cell Rep Med, 2023, 4(4):101007 Int J Biol Sci, 2021, 17(10):2417-2429 Int J Biol Sci, 2021, 17(10):2417-2429
S7140	TCID	TCID is a DUB inhibitor for ubiquitin C-terminal hydrolase L3 with IC50 of 0.6 μM, 125-fold selective to L1.	Nat Commun, 2022, 13(1):1700 Cell Chem Biol, 2021, S2451-9456(21)00213-0
S0515	PLpro inhibitor	PLpro inhibitor (compound 6) is a potent papain-like protease (PLpro)/deubiquitinase (DUBs) inhibitor with IC50 of 2.6 μM and EC50 of 13.1 μM that blocks SARS virus replication.	PLoS Pathog, 2023, 19(8):e1011592 PLoS Pathog, 2023, 19(8):e1011592 bioRxiv, 2022, 2022.08.06.503039
S8904	USP25/28 inhibitor AZ1	AZ1 is a potent and noncompetitive dual Inhibitors of the ubiquitin-specific protease (USP) 25/28 with IC50s of 0.62 μM and 0.7 μM in Ub-RH110 assay,respectively.	Mol Oncol, 2022, 10.1002/1878-0261.13217 Cancer Sci, 2022, 113-10:3463-3475
S6748	ML364	ML364 is a small molecule inhibitor of the deubiquitinase USP2 with an IC50 of 1.1 μM in a biochemical assay using an internally quenched fluorescent di-ubiquitin substrate.	Cell Insight, 2022, 1(4):100047 J Virol, 2020, JVI.01857-20
S0399	SJB2-043	SJB2-043 is a potent USP1 inhibitor that inhibits the activity of native USP1/UAF1 with IC50 of 544 nM.	Front Pharmacol, 2021, 12:695009
S6878	GSK2643943A	GSK2643943A is an inhibitor of deubiquitylating enzyme (DUB) with IC50 of 160 nM for USP20/Ub-Rho.	Nature, 2020, 10.1038/s41586-020-2928-y
S4922	NSC 632839	NSC 632839 is not only a DUB inhibitor, but also a deSUMOylase inhibitor, it inhibits USP2, USP7, and SENP2 with EC50 of 45 μM, 37 μM, and 9.8 μM, respectively.
E1633^New	BAY-805	BAY-805 is a potent, selective, and cell-active inhibitor that non-covalently targets the catalytic activity of USP21, a member of the ubiquitin-specific protease (USP) subfamily of deubiquitinating enzymes (DUBs).
E1479	I-138	I-138 is an orally active, potent reversible inhibitor of USP1-UAF1 with IC50 0f 4.1 nM. I-138 is structurally related to ML323 and induces the monoubiquitination of FANCD2 and PCNA in MDA-MB-436 cells and increases PCNA and FANCD2 monoubiquitination in HAP-1 USP1 WT cells.
S8967	XL177A	XL177A is a potent, selective and irreversible inhibitor of Ubiquitin specific peptidase 7 (USP7) with IC50 of 0.34 nM.
E1098	MF-094	MF-094, a potent and selective USP30 inhibitor (IC50=0.12 μM), accelerates diabetic wound healing by inhibiting the NLRP3 inflammasome.
E0392	Dubs-IN-1	Dubs-IN-1 is an active inhibitor of ubiquitin-specific proteases (USPs), with an IC50 of 0.85 μM for USP8.
E0389	DUBs-IN-2	DUBs-IN-2 is a potent inhibitor of USP7 and USP8 deubiquitinating enzymes.
E1330	Usp22i-S02	Usp22i-S02(USP22-IN-1, compound S02) is a potent inhibitor of ubiquitin specific peptidase 22 (USP22). It showed anticancer activity by suppressing Foxp3 expression in T-regulatory cells.
S6845	GRL0617	GRL0617 is a potent, selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLPro)/deubiquitinase with IC50 of 0.6 μM and Ki of 0.49 μM. GRL0617 inhibits SARS-CoV viral replication in Vero E6 cells with EC50 of 15 microM and has no associated cytotoxicity.	J Virol, 2024, e0085524.
S6883	HBX 19818	HBX19818 is a specific inhibitor of USP7 with an IC 50 of 28.1 μM.
S6933	GEN-6776	GNE-6776 is a potent, non-covalent, selective and orally bioavailable inhibitor of USP7 with IC50 of 1.34 μM and 0.61 μM for full length USP7 and USP7 catalytic domain, respectively.
E0947	Iu1-248	Iu1-248, a derivative of IU1, is a potent and selective ubiquitin specific peptidase 14 (USP14) inhibitor with an IC50 of 0.83 μM.
S6943	IU1-47	IU1-47 is a potent and specific inhibitor of USP14 with an IC50 of 0.6 μM. IU1-47 shows ∼33-fold selectivity for USP14 over USP5 (IsoT).
S0884	RA-9	RA-9 is a cell-permeable, potent and selective inhibitor of proteasome-associated deubiquitinating enzymes (DUBs) with favorable toxicity profile and anticancer activity. RA-9 selectively induces apoptosis in ovarian cancer cell lines.
E1214	KSQ-4279	KSQ-4279 (USP1-IN-1) is an orally bioavailable selective inhibitor of the ubiquitin specific protease 1 (USP1) with anti-proliferative activity. KSQ-4279 also exhibits synergistic activity in combination with PARP inhibitors.	Cancer Res, 2024, 84(20):3419-3434 Sci Adv, 2024, 10(46):eadp6567
S2913	BAY 11-7082	BAY 11-7082 (BAY 11-7821) is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 with IC50 of 0.19 μM and 0.96 μM, respectively. BAY 11-7082 induces apoptosis and S phase arrest in gastric cancer cells.	Nat Cancer, 2024, 10.1038/s43018-023-00712-x Redox Biol, 2024, 76:103323 Redox Biol, 2024, 70:103072
S7130	PR-619	PR-619 is a non-selective, reversible inhibitor of the deubiquitinylating enzymes (DUBs) with EC50 of 1-20 μM in a cell-free assay. PR-619 activates autophagy.	Nat Commun, 2024, 15(1):1642 Mol Cell, 2024, 84(16):3115-3127.e11 BMC Biol, 2024, 22(1):71
S7132	P5091	P5091 is a selective and potent inhibitor of ubiquitin-specific protease 7 (USP7) with EC50 of 4.2 μM and the closely related USP47.	J Exp Clin Cancer Res, 2024, 43(1):28 Int J Mol Sci, 2024, 25(5)2768 Nat Commun, 2023, 14(1):8481
S2243	Degrasyn (WP1130)	Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT). Degrasyn (WP1130) induces apoptosis and blocks autophagy.	Clin Cancer Res, 2023, 29(2):446-457 Clin Cancer Res, 2023, 29(2):446-457 Cancer Cell Int, 2023, 23(1):207
S7888	Spautin-1	Spautin-1 is a potent and specific autophagy inhibitor, and inhibits the deubiquitinating activity of USP10 and USP13 with IC50 of ∼0.6-0.7 μM. Spautin-1 enhances apoptosis.	Nat Commun, 2024, 15(1):9463 J Adv Res, 2024, S2090-1232(24)00025-0 Cancer Lett, 2024, 604:217258
S7133	P22077	P22077 is an inhibitor of ubiquitin-specific protease USP7 with EC50 of 8.6 μM, also inhibits the closely related USP47.	Int J Mol Sci, 2024, 25(5)2768 Hepatol Commun, 2024, 8(4)e0405 EMBO Rep, 2022, e54391
S7134	IU1	IU1 is a cell-permeable, reversible and selective proteasome inhibitor of human USP14 with IC50 of 4.7 μ M, 25-fold selective to IsoT. IU1 induces autophagy.	Redox Biol, 2024, 76:103318 Antioxidants (Basel), 2024, 13(1)114 Nat Commun, 2022, 13-1:5644
S4920	b-AP15	b-AP15 (NSC687852) is a deubiquitinases inhibitor for 19S proteasomes activity of Ub-AMC cleavage with IC50 of 2.1 μM.	J Transl Med, 2024, 22(1):193 Commun Biol, 2024, 7(1):25 Science, 2023, 380(6647):eadf2018
S7529	ML323	ML323 displays reversible, nanomolar inhibitory activity and excellent selectivity toward USP1/UAF1 with IC50 of 76 nM.	Nucleic Acids Res, 2024, gkae785 Mol Med, 2024, 30(1):121 Blood Adv, 2023, 7(13):3099-3112
S7135	LDN-57444	LDN-57444 is a reversible, competitive proteasome inhibitor for Uch-L1 with IC50 of 0.88 μM, 28-fold selectivity over isoform Uch-L3.	J Transl Med, 2024, 22(1):478 Cells, 2024, 13(9)737 Mol Cells, 2023, 46(8):476-485
S3692	NEM (N-Ethylmaleimide)	NEM (N-Ethylmaleimide) is an organic compound that is derived from maleic acid. It is an irreversible inhibitor of all cysteine peptidases, with alkylation occurring at the active site thiol group. N-Ethylmaleimide (NEM) inactivates endogenous deubiquitinating enzymes (DUBs). N-Ethylmaleimide (NEM) specifically inhibits phosphate transport in mitochondria.	BMC Biol, 2024, 22(1):71 Cell Rep Med, 2023, 10.1016/j.xcrm.2023.101286 Int J Mol Sci, 2023, 25(1)423
S8288	VLX1570	VLX1570 is a competitive inhibitor of proteasome DUB activity, with an IC50 of ~10 μM in vitro.	Commun Biol, 2024, 7(1):25 PLoS One, 2022, 17(7):e0271245 Cancer Sci, 2021, 112(8):3302-3313
S6877	EOAI3402143	EOAI3402143 is a dose-dependent inhibitor of Usp9x, Usp24 and Usp5 that increases tumor cell apoptosis, and fully blocks or regresses myeloma tumors in mice.	Cell Rep Med, 2023, 4(4):101007 Int J Biol Sci, 2021, 17(10):2417-2429 Int J Biol Sci, 2021, 17(10):2417-2429
S7140	TCID	TCID is a DUB inhibitor for ubiquitin C-terminal hydrolase L3 with IC50 of 0.6 μM, 125-fold selective to L1.	Nat Commun, 2022, 13(1):1700 Cell Chem Biol, 2021, S2451-9456(21)00213-0
S0515	PLpro inhibitor	PLpro inhibitor (compound 6) is a potent papain-like protease (PLpro)/deubiquitinase (DUBs) inhibitor with IC50 of 2.6 μM and EC50 of 13.1 μM that blocks SARS virus replication.	PLoS Pathog, 2023, 19(8):e1011592 PLoS Pathog, 2023, 19(8):e1011592 bioRxiv, 2022, 2022.08.06.503039
S8904	USP25/28 inhibitor AZ1	AZ1 is a potent and noncompetitive dual Inhibitors of the ubiquitin-specific protease (USP) 25/28 with IC50s of 0.62 μM and 0.7 μM in Ub-RH110 assay,respectively.	Mol Oncol, 2022, 10.1002/1878-0261.13217 Cancer Sci, 2022, 113-10:3463-3475
S6748	ML364	ML364 is a small molecule inhibitor of the deubiquitinase USP2 with an IC50 of 1.1 μM in a biochemical assay using an internally quenched fluorescent di-ubiquitin substrate.	Cell Insight, 2022, 1(4):100047 J Virol, 2020, JVI.01857-20
S0399	SJB2-043	SJB2-043 is a potent USP1 inhibitor that inhibits the activity of native USP1/UAF1 with IC50 of 544 nM.	Front Pharmacol, 2021, 12:695009
S6878	GSK2643943A	GSK2643943A is an inhibitor of deubiquitylating enzyme (DUB) with IC50 of 160 nM for USP20/Ub-Rho.	Nature, 2020, 10.1038/s41586-020-2928-y
S4922	NSC 632839	NSC 632839 is not only a DUB inhibitor, but also a deSUMOylase inhibitor, it inhibits USP2, USP7, and SENP2 with EC50 of 45 μM, 37 μM, and 9.8 μM, respectively.
E1633^New	BAY-805	BAY-805 is a potent, selective, and cell-active inhibitor that non-covalently targets the catalytic activity of USP21, a member of the ubiquitin-specific protease (USP) subfamily of deubiquitinating enzymes (DUBs).
E1479	I-138	I-138 is an orally active, potent reversible inhibitor of USP1-UAF1 with IC50 0f 4.1 nM. I-138 is structurally related to ML323 and induces the monoubiquitination of FANCD2 and PCNA in MDA-MB-436 cells and increases PCNA and FANCD2 monoubiquitination in HAP-1 USP1 WT cells.
S8967	XL177A	XL177A is a potent, selective and irreversible inhibitor of Ubiquitin specific peptidase 7 (USP7) with IC50 of 0.34 nM.
E1098	MF-094	MF-094, a potent and selective USP30 inhibitor (IC50=0.12 μM), accelerates diabetic wound healing by inhibiting the NLRP3 inflammasome.
E0392	Dubs-IN-1	Dubs-IN-1 is an active inhibitor of ubiquitin-specific proteases (USPs), with an IC50 of 0.85 μM for USP8.
E0389	DUBs-IN-2	DUBs-IN-2 is a potent inhibitor of USP7 and USP8 deubiquitinating enzymes.
E1330	Usp22i-S02	Usp22i-S02(USP22-IN-1, compound S02) is a potent inhibitor of ubiquitin specific peptidase 22 (USP22). It showed anticancer activity by suppressing Foxp3 expression in T-regulatory cells.
S6845	GRL0617	GRL0617 is a potent, selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLPro)/deubiquitinase with IC50 of 0.6 μM and Ki of 0.49 μM. GRL0617 inhibits SARS-CoV viral replication in Vero E6 cells with EC50 of 15 microM and has no associated cytotoxicity.	J Virol, 2024, e0085524.
S6883	HBX 19818	HBX19818 is a specific inhibitor of USP7 with an IC 50 of 28.1 μM.
S6933	GEN-6776	GNE-6776 is a potent, non-covalent, selective and orally bioavailable inhibitor of USP7 with IC50 of 1.34 μM and 0.61 μM for full length USP7 and USP7 catalytic domain, respectively.
E0947	Iu1-248	Iu1-248, a derivative of IU1, is a potent and selective ubiquitin specific peptidase 14 (USP14) inhibitor with an IC50 of 0.83 μM.
S6943	IU1-47	IU1-47 is a potent and specific inhibitor of USP14 with an IC50 of 0.6 μM. IU1-47 shows ∼33-fold selectivity for USP14 over USP5 (IsoT).
S0884	RA-9	RA-9 is a cell-permeable, potent and selective inhibitor of proteasome-associated deubiquitinating enzymes (DUBs) with favorable toxicity profile and anticancer activity. RA-9 selectively induces apoptosis in ovarian cancer cell lines.
E1214	KSQ-4279	KSQ-4279 (USP1-IN-1) is an orally bioavailable selective inhibitor of the ubiquitin specific protease 1 (USP1) with anti-proliferative activity. KSQ-4279 also exhibits synergistic activity in combination with PARP inhibitors.	Cancer Res, 2024, 84(20):3419-3434 Sci Adv, 2024, 10(46):eadp6567
E1633^New	BAY-805	BAY-805 is a potent, selective, and cell-active inhibitor that non-covalently targets the catalytic activity of USP21, a member of the ubiquitin-specific protease (USP) subfamily of deubiquitinating enzymes (DUBs).

Choose Selective DUB Inhibitors